Letter to the Editor Regarding: "Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry".
作者信息
Liu Zhongxing, Tian Mengzhe, Duan Lincheng
机构信息
Dujiangyan Traditional Chinese Medicine Hospital, Chengdu, Sichuan, China.
Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
出版信息
Rheumatol Ther. 2025 Apr;12(2):397-399. doi: 10.1007/s40744-024-00738-2. Epub 2025 Jan 18.
Abstract
摘要
相似文献
1
Letter to the Editor Regarding: "Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry".致编辑的信：关于“日本类风湿关节炎患者的恶性肿瘤发病率及其与生物性改善病情抗风湿药物的关联：来自IORRA患者登记处的时间依赖性分析”
Rheumatol Ther. 2025 Apr;12(2):397-399. doi: 10.1007/s40744-024-00738-2. Epub 2025 Jan 18.
2
Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry.日本类风湿关节炎患者的恶性肿瘤发病率及其与生物改善病情抗风湿药的关联：来自IORRA患者登记处的时间依赖性分析
Rheumatol Ther. 2024 Oct;11(5):1181-1195. doi: 10.1007/s40744-024-00689-8. Epub 2024 Jul 17.
3
Trends in risks of malignancies in Japanese patients with rheumatoid arthritis: Analyses from a 14-year observation of the IORRA cohort.日本类风湿关节炎患者恶性肿瘤风险趋势：IORRA 队列 14 年观察分析。
Mod Rheumatol. 2023 Jul 4;33(4):715-722. doi: 10.1093/mr/roac085.
4
Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study.与日本类风湿关节炎患者肌少症相关的因素：IORRA 队列研究结果。
Clin Rheumatol. 2024 Jan;43(1):521-526. doi: 10.1007/s10067-023-06779-2. Epub 2023 Sep 21.
5
Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.基于日本 IORRA 观察性队列研究的真实世界数据，对类风湿关节炎患者的生物疾病修正抗风湿药物进行药物经济学分析。
Mod Rheumatol. 2017 Mar;27(2):227-236. doi: 10.1080/14397595.2016.1205799. Epub 2016 Jul 29.
6
Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort.日本类风湿性关节炎患者在新冠疫情期间治疗依从性和行为的变化：IORRA队列横断面研究结果
Mod Rheumatol. 2022 Oct 15;32(6):1193-1195. doi: 10.1093/mr/roab120.
7
Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort.类风湿关节炎患者中生物改善病情抗风湿药物在随机对照试验和真实世界环境中的患者人群和疗效/有效性差异——使用 IORRA 队列。
Mod Rheumatol. 2022 Jul 1;32(4):675-685. doi: 10.1093/mr/roab067.
8
Increasing fracture incidence over 13 years in patients with rheumatoid arthritis from the IORRA cohort.来自IORRA队列的类风湿关节炎患者在13年期间骨折发生率不断上升。
J Bone Miner Metab. 2025 Apr 7. doi: 10.1007/s00774-025-01598-8.
9
Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: A nationwide cohort study in Japan.与普通人群相比，接受生物性病情改善抗风湿药物治疗的类风湿关节炎患者的恶性肿瘤风险：日本一项全国性队列研究。
Mod Rheumatol. 2016 Sep;26(5):642-50. doi: 10.3109/14397595.2016.1141740. Epub 2016 Mar 11.
10
Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.改善病情抗风湿药与细胞毒性药物在类风湿关节炎治疗中的作用。
Am J Med. 1988 Oct 14;85(4A):39-44. doi: 10.1016/0002-9343(88)90361-0.
本文引用的文献
1
Risk of Gastric and Small Intestinal Cancer in Patients With Lynch Syndrome: Data From a Large, Community-Based US Population.林奇综合征患者的胃癌和小肠癌风险：来自大型社区为基础的美国人群的数据。
Clin Transl Gastroenterol. 2024 Sep 1;15(9):e1. doi: 10.14309/ctg.0000000000000739.
2
Cardiovascular health, polygenic risk score, and cancer risk: a prospective cohort study.心血管健康、多基因风险评分与癌症风险：一项前瞻性队列研究。
Am J Clin Nutr. 2024 Oct;120(4):785-793. doi: 10.1016/j.ajcnut.2024.07.033. Epub 2024 Aug 10.
3
Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry.日本类风湿关节炎患者的恶性肿瘤发病率及其与生物改善病情抗风湿药的关联：来自IORRA患者登记处的时间依赖性分析
Rheumatol Ther. 2024 Oct;11(5):1181-1195. doi: 10.1007/s40744-024-00689-8. Epub 2024 Jul 17.
4
Clinicopathological Characteristics and Risk Factors of Young-Onset Gastric Carcinoma: A Systematic Review and Meta-analysis.青年胃癌的临床病理特征及危险因素：系统评价和荟萃分析。
Clin Transl Gastroenterol. 2024 Jun 1;15(6):e1. doi: 10.14309/ctg.0000000000000714.
5
Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer.健康生活方式与癌症风险：可改变的癌症预防风险因素。
Nutrients. 2024 Mar 11;16(6):800. doi: 10.3390/nu16060800.
6
Triple Primary Cancers: An Analysis of Genetic and Environmental Factors.三原发性癌症：遗传与环境因素分析
Cancer Prev Res (Phila). 2024 May 2;17(5):209-215. doi: 10.1158/1940-6207.CAPR-23-0395.
7
Association between a family history of cancer and multiple primary lung cancer risks: a population-based analysis from China.家族癌症史与多原发肺癌风险的关联：来自中国的基于人群的分析。
BMC Pulm Med. 2023 Oct 31;23(1):415. doi: 10.1186/s12890-023-02676-1.
8
Lifestyle, genetic risk and incidence of cancer: a prospective cohort study of 13 cancer types.生活方式、遗传风险与癌症发病风险：13 种癌症的前瞻性队列研究。
Int J Epidemiol. 2023 Jun 6;52(3):817-826. doi: 10.1093/ije/dyac238.
9
Diabetes, metformin use and risk of non-Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative.糖尿病、二甲双胍的使用与绝经后妇女患非霍奇金淋巴瘤的风险：妇女健康倡议中的前瞻性队列分析。
Int J Cancer. 2023 Apr 15;152(8):1556-1569. doi: 10.1002/ijc.34376. Epub 2022 Dec 7.
10
A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors.全球范围内对近期胃肠道癌症的趋势和与生活方式相关的风险因素的评估。
Cancer Commun (Lond). 2021 Nov;41(11):1137-1151. doi: 10.1002/cac2.12220. Epub 2021 Sep 25.
Zotero 插件